Information  X 
Enter a valid email address

EPIC/TIDM matching '0H7R'

Date
Time Source
Company
Announcement
26 Jun 2019 1:00 pm GNW Report Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Appoints Dr. Victor Paulus Senior Vice President of Regulatory Affairs
18 Jun 2019 1:29 pm GNW Report Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Receives FDA Fast Track Designation for ABO-202 AAV9 Gene Therapy in CLN1 Disease
21 May 2019 1:00 pm GNW Report Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Announces FDA Clearance of Investigational New Drug Application for ABO-202 Gene Therapy in CLN1 Disease
14 May 2019 1:00 pm GNW Report Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Treats First Patient in Second Cohort of Phase 1/2 Clinical Trial for ABO-101 in Sanfilippo Syndrome Type B (MPS IIIB)
10 May 2019 9:15 pm GNW Report Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Reports First Quarter 2019 Financial Results and Business Highlights
08 May 2019 1:30 pm GNW Report Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Announces Presentation of EB-101 Data at Society for Investigative Dermatology Annual Meeting
01 May 2019 1:00 pm GNW Report Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Reports Preclinical Data Demonstrating Broad Therapeutic Potential of AIM™ Gene Therapy in Retinal Diseases at Association for Research in Vision and Ophthalmology Annual Meeting
30 Apr 2019 1:00 pm GNW Report Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics to Report New Preclinical Data Demonstrating Therapeutic Potential of ABO-401 for Treatment of Cystic Fibrosis at American Society of Gene and Cell Therapy Annual Meeting
15 Apr 2019 7:41 pm GNW Report Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics to Present Data for ABO-401 in Cystic Fibrosis and Retinal Disorders at the American Society of Gene and Cell Therapy Annual Meeting
04 Apr 2019 1:25 pm GNW Report Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Receives FDA Fast Track Designation for ABO-101 for Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
18 Mar 2019 8:45 pm GNW Report Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
31 Jan 2019 1:00 pm GNW Report Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics to Present New Supportive Data for Novel Gene Therapies at WORLDSymposium™
09 Nov 2018 9:20 pm GNW Report Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Reports Third Quarter 2018 Financial Results and Business Highlights
05 Nov 2018 12:00 pm GNW Report Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics and REGENXBIO Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector
18 Oct 2018 1:03 pm GNW Report Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Appoints João Siffert, M.D. Head of Research and Development and Chief Medical Officer
12 Sep 2018 1:45 pm GNW Report Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Announces Authorization to Commence Phase 1/2 Gene Therapy Clinical Study for Patients with MPS IIIB in Spain
09 Aug 2018 9:20 pm GNW Report Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Reports Second Quarter 2018 Financial Results and Business Highlights
11 May 2018 1:15 pm GNW Report Factsheet Abeona Therapeutics Inc (0H7R) Abeona Therapeutics Reports First Quarter 2018 Financial Results and Business Highlights
23 Apr 2018 1:15 pm GNW Report Factsheet Abeona Therapeutics Inc (0H7R) Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA
20 Apr 2018 1:15 pm GNW Report Factsheet Abeona Therapeutics Inc (0H7R) Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease
02 Apr 2018 1:15 pm GNW Report Factsheet Abeona Therapeutics Inc (0H7R) Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer
16 Mar 2018 9:32 pm GNW Report Factsheet Abeona Therapeutics Inc (0H7R) Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights
07 Feb 2018 1:45 pm GNW Report Factsheet Abeona Therapeutics Inc (0H7R) Abeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical Trial
02 Feb 2018 1:45 pm GNW Report Factsheet Abeona Therapeutics Inc (0H7R) Abeona Therapeutics Announces Upcoming Presentations at the 14th Annual WORLDSymposium
29 Jan 2018 1:45 pm GNW Report Factsheet Abeona Therapeutics Inc (0H7R) Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis Bullosa
20 Dec 2017 1:45 pm GNW Report Factsheet Abeona Therapeutics Inc (0H7R) Abeona Therapeutics Enrolls First Patient in ABO-101 Phase 1/2 Clinical Trial for MPS IIIB
15 Nov 2017 1:25 pm GNW Report Factsheet Abeona Therapeutics Inc (0H7R) Abeona Reports Third Quarter 2017 Financial Results and Recent Business Highlights
13 Nov 2017 1:45 pm GNW Report Factsheet Abeona Therapeutics Inc (0H7R) Abeona Management to Present at Multiple Conferences in November
09 Nov 2017 1:45 pm GNW Report Factsheet Abeona Therapeutics Inc (0H7R) Abeona Enrolls First Subject in Spain in Ongoing Phase 1/2 Clinical Trial in MPS IIIA
04 Oct 2017 1:52 pm GNW Report Factsheet Abeona Therapeutics Inc (0H7R) Abeona Therapeutics Announces Dedication of Commercial Gene Therapy Manufacturing Facility in Cleveland, Ohio
16 Aug 2017 2:38 pm GNW Report Factsheet Abeona Therapeutics Inc (0H7R) Abeona Therapeutics Announces Pivotal Expansion of ABO-102 Gene Therapy Clinical Trials in Sanfilippo Syndrome Type A


Company Announcements Archive »

 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t